Hamza Hashmi

@End_myeloma on MajesTEC-3 competing-risk analysis at #IMS26: Tec-Dara vs DPd/DVd in RRMM, 1–3 prior LOTs • Progression sHR 0.10 • NRM similar (28 vs 26) • OS HR 0.22 after 10 mo Early infection deaths → IgRT + antimicrobial prophylaxis is a must. #mmsm @Myeloma_Society https://t.co/J9QwgmmdCZ

@HadidiSamer It would be interesting to see if pts who were CD38 non refractory (15%) had similar outcomes to those in MajesTEC-3. In other words, do we need CD38+Tec ot TEC alone is sufficient.

@kansagraMD Great to see Talq become q4 week after C4-6 and pom 2mg only. Tal-DP vs Tal-D should be looked at in HRCG, EMD, and Functionally high-risk myeloma subgroups. 2yr PFS looks similar to MajesTEC-3. This could be a great option for post 2L CAR T relapse. Will wait for https://t.co/jSHlySQ8Bn

#IMS26 recap: CERVINO trial: Etentamig in triple class exposed RRMM: ➡️Unlike other BsAb monotherapy trials, this was a phase III RCT but with suboptimal control arms (Kd,EPd,SVd) ➡️1 step-up dose → monthly + CRS 28% (0% w/ ppx toci) makes it very conducive for https://t.co/iKZxko5t9g

CERVINO (Etentamig Phase 3) @PlasmaCellPete on 🎯#IMS26: CERVINO Ph3: Etentamig superior to SAT (EPD, SVD, KD) in heavily pre-treated triple-class exposed RRMM 💡ORR 74% vs 45%, PFS at 12m NR (60%) vs 6m, OS benefit signal despite many SAT pts receiving TCRT at relapse 💡CRS 28% https://t.co/p9YDE8TJ7P

Recap from #IMS26 🧵5-year data from CARTITUDE-2 Cohort A for early line CAR-T: ➡️Cilta-cel infusion in RRMM with 1–3 prior lines (PI-exposed, len-refractory): 💡50% Dara refractory, n=20 but longest follow up for early line CAR-T ➡️50% of patients alive and progression-free https://t.co/mE2Yht421p

CARTITUDE-2 Cohort A, PA-288) 5-year data from CARTITUDE-2 Cohort A at #IMS26 🧵 poster session A single cilta-cel infusion in RRMM with 1–3 prior lines (PI-exposed, len-refractory 💡50% of patients alive and progression-free at 5+ years with no further therapy. 💡5-yr PFS https://t.co/1JC5YO8h0F

🧵 EXCALIBER-RRMM, now in @TheLancetOncol and presented in plenary session at #IMS26. https://t.co/v9EBfpEwez 💡Iberdomide + dara + dex vs DVd in RRMM after 1–2 prior lines: the first myeloma approval built on MRD. ➡️2-stage seamless phase 3 (939 randomised), Stage 1 selected iberdomide 1.0 mg over 1.3/1.6 m ➡️Dual primary endpoints: MRD-neg CR (10⁻⁵, NGF) + PFS ➡️Excluded: anti-CD38- or bortezomib-refractory disease ➡️MRD analysis: first 420 patients 💡Efficacy (median FU ~15 mo): ➡️ MRD-neg CR: 40% vs 20% (OR 2.75, p<0.0001) ➡️ ≥CR: 46% vs 25% ➡️Time to MRD-CR ~9m ➡️Consistent across sub groups, except age>75, HR CG, soft tissue plasmacytoma ➡️Encouraging, but PFS (800-pt cohort) and OS are pending. MRD is a surrogate until PFS confirms it. 💡Safety: ➡️Neutropenia is the main safety issue: Grade 3+: 84% vs 11% ➡️Onset ~3 weeks in; median duration 8 days ➡️~80% in cycles 1–2, then ~15–20% later with G-CSF, low rates of febrile neutropenia 5.5% ➡️Dose reduction for neutropenia in 13% ➡️Infections G3+: 40% vs 20%. After DMC review, the protocol was amended to strengthen antibacterial prophylaxis. ➡️VTE 6.4% despite mandatory prophylaxis; arterial events 3.4% (MI 2%, stroke 1.5%) ➡️SPMs 7% vs 5% ➡️Serious AEs: 58% vs 40%, and ~75% in patients ≥75

EXCALIBER-RRMM (Iberdomide-Dd vs DVd) by @SagarLonialMD 🏆#IMS26: EXCALIBER-RRMM: IberDd doubles MRD-neg CR vs DVd in 420 pts (40% vs 20%, P&lt;0.0001). 💡Non-Heme AE: Diarrhea 30%, fatigue 25%, rash 10%, mostly G1, seemingly better than Len based combinations 💡Gr3+ neutropenia https://t.co/vjD9YDbW5G

PERSEUS long-term follow-up at #IMS26: D-VRd → DR vs VRd → R in transplant-eligible NDMM (median follow-up &gt;80 mo) 💡72-mo PFS: 81% vs 56% 💡Median PFS: not reached vs 80 mo 💡The benefit held across risk groups: 🟢 Standard risk: 88% vs 63% (HR 0.27) 🔴 High risk: 55.0% vs 33% https://t.co/L310hqwcEC

GMMG-HD10/MajesTEC-5 Arm E (Tal-DR induction) 💪 #IMS26: Tal-DR induction in TE-NDMM (MajesTEC-5 Arm E) delivers 💡ORR 90%, 90% MRD-neg pre-ASCT, with lower Gr3-4 infections than BCMA-based arms 💡Encouraging, but n=20 and 4/20 discontinued Tal for AEs (vertigo, balance, https://t.co/pG3ShunSvJ

MIDAS (Isa-Iberdomide maintenance) 🧬 #IMS26: MIDAS: Isatuximab + iberdomide maintenance drives MRD conversion in MRD-positive TE-NDMM pts post Isa-KRd: 💡MRD-neg (10⁻⁶) rates rising 40%→58%. 💡Encouraging depth, but only 1-yr data so far 💡will conversions translate into https://t.co/wbs0wW3grk

GEM2014MAIN (MRD-guided maintenance discontinuation) 🎯 #IMS26: GEM2014MAIN: MRD-neg pts who stopped maintenance at 2yrs had median PFS not reached vs 3.5yrs for MRD-positive pts who continued. 💡50% remained progression-free at 7yrs. 💡Early MRD neg &gt; late MRD neg 💡sustained https://t.co/TJI1PPYAf1